KemantaneКемантан
A synthetic adamantane compound studied in Russian immune research, including historical clinical reports.
What the studies found
Study involving people · 1990
Kemantane in recurrent aphthous stomatitis
- Lesion healing and remission
- Earlier epithelialization and longer remissions reported in fibrous and scarring forms.No numerical differences or comparator denominators available.
The authors reported faster lesion healing and longer remission in fibrous or scarring recurrent aphthous stomatitis. No effect size or time-to-healing figures appear in the abstract.
Study notes · methods, sources and limitations
Participants or model 30 Kemantane-treated patients with severe recurrent aphthous stomatitis.
Design Clinical and blood-marker assessments in 30 treated patients with severe recurrent aphthous stomatitis.
Important limitations
- The abstract does not give the dose, schedule, comparator size, allocation methods or adverse-event counts.
- Dose, course length, relapse duration and harms require the full article.
Stomatologiia (Mosk). 1990;69(1):31–33. · Indexed abstract
Comparison in people · 1991
Fourteen treated patients showed changes in immune markers
- T-cell count and blast formation
- Increases reported in the 14 treated patients.Unchanged or declining measures reported in untreated patients.
- T-cell functional activity
- Upward trend reported in treated patients.
In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.
Study notes · methods, sources and limitations
Participants or model 219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.
Design Pulmonary tuberculosis observational cohort (219). Of 136 with respiratory viral infection, 14 received Kemantane.
Important limitations
- Treatment selection, dose, comparator denominator and the numerical immune effects require the full text. The 19.1% clinical aggravation figure describes the association with infection. A Kemantane effect on tuberculosis outcomes was not quantified.
- The 19.1% aggravation figure concerned viral infection. It was not a between-arm estimate for Kemantane.
Probl Tuberk. 1991;(6):23–26. · Indexed abstract
Study involving people · 1991
Clinical pharmacokinetics of Kemantane in bronchial disease
- Parent compound in blood
- Little or no detectable parent Kemantane. The authors evaluated exposure through its major active metabolite.
Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.
Study notes · methods, sources and limitations
Participants or model Patients with bronchial disease. Enrollment was not stated in the abstract.
Design Gas–liquid chromatography in patients with bronchial disease.
Important limitations
- The abstract does not provide the dose, sampling schedule or numerical pharmacokinetic estimates. This report assesses exposure.
- The abstract provides no numerical estimates, dose, sampling schedule or group sizes.
Farmakol Toksikol. 1991;54(1):57–59. · Indexed abstract
About Kemantane
Names in this research collection
ADK-412 · Kemantan
Research background
An adamantane preparation used as an immune-pharmacology comparator in the historical ADK program. This entry documents those experiments; formulation-specific clinical evidence remains unreviewed.
- Compound class
- Experimental adamantane / analogue
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Human efficacy results unavailable
Study methods
Source-specific animal, chemistry, patent or dissertation evidence
Independent replication
Independent replication not established; translations are not separate experiments
Source access
Access and review depth appear with each linked record
Safety evidence
Human safety and interactions not established; animal activity is not a safe-use recommendation
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Study involving people · 1990
Kemantane in recurrent aphthous stomatitis
The authors reported faster lesion healing and longer remission in fibrous or scarring recurrent aphthous stomatitis. No effect size or time-to-healing figures appear in the abstract.
Study notes and original source
Kemantane in recurrent aphthous stomatitis
N. V. Terekhova, V. V. Khazanova, E. A. Zemskaia, et al. · Stomatologiia (Mosk). 1990;69(1):31–33.
The authors reported faster lesion healing and longer remission in fibrous or scarring recurrent aphthous stomatitis. No effect size or time-to-healing figures appear in the abstract.
Results and tables
Reported findings and study design
Findings described in words
Clinical and blood-marker assessments in 30 treated patients with severe recurrent aphthous stomatitis.
Population or model 30 Kemantane-treated patients with severe recurrent aphthous stomatitis.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Lesion healing and remission | Earlier epithelialization and longer remissions reported in fibrous and scarring forms. | No numerical differences or comparator denominators available. |
Dose, course length, relapse duration and harms require the full article.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 30 Kemantane-treated patients with severe recurrent aphthous stomatitis.
- Source reviewed
- Indexed English abstract of the original Russian journal report.
Study limitations
- The abstract does not give the dose, schedule, comparator size, allocation methods or adverse-event counts.
Reviewed 2026-11-14.
Comparison in people · 1991
Kemantane in tuberculosis patients with intercurrent respiratory viral infection
In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.
Study notes and original source
Kemantane in tuberculosis patients with intercurrent respiratory viral infection
N. V. Kossii, I. S. Khomenko, V. Ia. Gergert · Probl Tuberk. 1991;(6):23–26.
In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.
Results and tables
Reported findings and study design
Findings described in words
Pulmonary tuberculosis observational cohort (219). Of 136 with respiratory viral infection, 14 received Kemantane.
Population or model 219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| T-cell count and blast formation | Increases reported in the 14 treated patients. | Unchanged or declining measures reported in untreated patients. |
| T-cell functional activity | Upward trend reported in treated patients. |
The 19.1% aggravation figure concerned viral infection. It was not a between-arm estimate for Kemantane.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.
- Source reviewed
- Indexed English abstract of the original Russian journal report.
Study limitations
- Treatment selection, dose, comparator denominator and the numerical immune effects require the full text.
- The 19.1% clinical aggravation figure describes the association with infection. A Kemantane effect on tuberculosis outcomes was not quantified.
Reviewed 2026-11-14.
Study involving people · 1991
Clinical pharmacokinetics of Kemantane in bronchial disease
Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.
Study notes and original source
Clinical pharmacokinetics of Kemantane in bronchial disease
S. S. Boiko, V. P. Zherdev, N. A. Kisliak · Farmakol Toksikol. 1991;54(1):57–59.
Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.
Results and tables
Reported findings and study design
Findings described in words
Gas–liquid chromatography in patients with bronchial disease.
Population or model Patients with bronchial disease. Enrollment was not stated in the abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Parent compound in blood | Little or no detectable parent Kemantane. The authors evaluated exposure through its major active metabolite. |
The abstract provides no numerical estimates, dose, sampling schedule or group sizes.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Patients with bronchial disease. Enrollment was not stated in the abstract.
- Source reviewed
- Indexed English abstract of the original Russian journal report.
Study limitations
- The abstract does not provide the dose, sampling schedule or numerical pharmacokinetic estimates. This report assesses exposure.
Reviewed 2026-11-14.
Experiment described in a patent · 1990
Kemantane: historical immunostimulatory-use disclosure — SU1586711A1
Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.
Peripheral-vascular case · Walking distance reportedly increased from 100–150 m to 500–700 m · One patient; concurrent care and standardized testing not established · After a two-week course; one-year observation mentioned
Study notes and original source
Kemantane: historical immunostimulatory-use disclosure — SU1586711A1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Нинель Григорьевна Арцимович, Татьяна Александровна Фадеева, Юлия Анатольевна Шалыминова, Татьяна Евгеньевна Захарова, Ираида Андреевна Асташина, Ольга Васильевна Щербакова, Михаил Исаевич Шмарьян, Александр Борисович Вайншток, Нина Васильевна Климова, Лидия Николаевна Лаврова, Александр Петрович Сколдинов · SU1586711A1 · patent family 20708410
Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.
Results and tables
Reported patent results
Reported findings
Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.
Kemantane patent describes selected clinical cases of vascular and respiratory disease without a controlled cohort.
Population or model Kemantane patent describes selected clinical cases of vascular and respiratory disease without a controlled cohort.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Peripheral-vascular case | Walking distance reportedly increased from 100–150 m to 500–700 m | One patient; concurrent care and standardized testing not established · After a two-week course; one-year observation mentioned |
| Ulcer case | Foot ulcers reportedly healed during treatment | Another individual case, not a controlled ulcer-healing rate · Two weeks; favorable one-year observation described |
| Chronic-bronchitis case | E-rosette marker 12% → 50%, alongside improved symptoms | Single-patient immune-marker change · Around day 10 |
Selected cases and marker changes do not establish general immune benefit, autoimmune disease control, clinical efficacy or long-term safety.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Kemantane patent describes selected clinical cases of vascular and respiratory disease without a controlled cohort.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Historical disclosure is not a modern controlled clinical trial and does not establish autoimmune benefit.
- Selected cases and marker changes do not establish general immune benefit, autoimmune disease control, clinical efficacy or long-term safety.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Animal research · Year unconfirmed
Role of neurotropic adamantane-containing compounds in the regulation of immunity
This preparation is included in an immune-regulation dissertation trail. A reliable preparation-specific effect estimate has not been extracted; findings emphasized for ADK-910 cannot be assigned to it.
Study notes and original source
Role of neurotropic adamantane-containing compounds in the regulation of immunity
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
· Dissertation author’s abstract; third-party Russian transcription
The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
- Population / setting
- Multiple mouse strains and laboratory immune assays
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
- Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.
Reviewed 2026-10-03.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗